Volume : 13, Issue : 05, May – 2026
Title:
FORMULATION AND EVALUATION OF PH-DEPENDENT EUDRAGIT S-100 COATED MATRIX TABLETS OF TOFACITINIB CITRATE FOR COLON TARGETED DRUG DELIVERY
Authors :
Satyam Pahariya*, Akanksha Tiwari, Rekha Rani, Priyanka Keshri
Abstract :
The goal of the current study was to create and assess pH-dependent Eudragit S-100 coated matrix tablets containing tofacitinib citrate for colon-targeted medication delivery. Using chitosan and Carbopol 940 P as release-retarding polymers and citric acid and sodium bicarbonate as gas-generating agents, matrix tablets were made by direct compression. Bulk density, tapped density, compressibility index, Hausner ratio, hardness, thickness, friability, weight variation, drug content, floating lag time, and total floating duration were among the pre-compression and post-compression parameters that were assessed for a total of nine formulations (F1–F9). Every formulation showed adequate buoyancy behavior and acceptable physicochemical properties. All formulations displayed sustained release characteristics in in vitro drug release experiments, with formulation F8 exhibiting optimal drug release with a floating lag time of 28 ± 2 seconds and a cumulative drug release of 98.95 ± 1.40% at 12 hours. The optimized formulation followed Higuchi diffusion kinetics with a non-Fickian diffusion mechanism, according to drug release kinetic experiments. The optimized formulation’s good stability was confirmed by stability testing conducted under accelerated settings, which showed no appreciable changes in physical appearance, drug content, hardness, and drug release profile.
According to the study’s findings, Eudragit S-100 coated matrix tablets of tofacitinib citrate may be a viable method for efficient colon-targeted medication delivery with extended drug release and enhanced therapeutic efficacy.
Keywords: Tofacitinib citrate, Colon targeted drug delivery, Eudragit S-100, Matrix tablets, Chitosan, Carbopol 940 P, Floating tablets, Sustained release, pH-dependent coating, Drug release kinetics.
Cite This Article:
Please cite this article in press Satyam Pahariya et al., Formulation And Evaluation Of Ph-Dependent Eudragit S-100 Coated Matrix Tablets Of Tofacitinib Citrate For Colon Targeted Drug Delivery.., Indo Am. J. P. Sci, 2026; 13(05).
REFERENCES:
1. Muhammed RA, Mohammed S, Visht S, Yassen AO. A review on development of colon targeted drug delivery system. Int J Appl Pharm. 2024;16(2):12-27.
2. Banerjee A, Pathak S, Subramanium VD, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today. 2017;22(8):1224-1232.
3. Mishra AS, Ghosh B, Malliappan SP, Dutta G, Vasanthan M. Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems. RSC Adv. 2026;16(11):10022-10059.
4. Kshirsagar SJ, Bhalekar MR, Umap RR. In vitro in vivo comparison of two pH sensitive Eudragit polymers for colon specific drug delivery. J Pharm Sci Res. 2009;1(4):61-68.
5. Sardou HS, Vosough PR, Abbaspour M, Akhgari A, Sathyapalan T, Sahebkar A. A review on curcumin colon-targeted oral drug delivery systems for the treatment of inflammatory bowel disease. Inflammopharmacology. 2023;31(3):1095-1105.
6. Palasik BN, Wang H. Tofacitinib, the first oral Janus kinase inhibitor approved for adult ulcerative colitis. J Pharm Pract. 2021;34(6):913-921.
7. Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech. 2015;16(4):731-741.
8. Gvozdeva Y, Staynova R. pH-dependent drug delivery systems for ulcerative colitis treatment. Pharmaceutics. 2025;17(2):226.
9. Mehta R, Chawla A, Sharma P, Pawar P. Formulation and in vitro evaluation of Eudragit S100 coated naproxen matrix tablets for colon targeted drug delivery system. J Adv Pharm Technol Res. 2013;4(1):31-41.
10. Rohit M, Chawla A, Sharma P, Pawar P. Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system. J Adv Pharm Technol Res. 2013;4(1):31-41.
11. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech. 2006;7:E1-E9.
12. Chandran S, Asghar LF, Mantha N. Design and evaluation of ethyl cellulose based matrix tablets of ibuprofen with pH modulated release kinetics. Indian J Pharm Sci. 2008;70:596-602.
13. Tugcu Demiroz F, Acarturk F, Takka S, Konus Boyunaga O. In vitro and in vivo evaluation of mesalazine guar gum matrix tablets for colonic drug delivery. J Drug Target. 2004;12:105-112.
14. Khan MZ, Prebeg Z, Kurjakovic N. A pH dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Release. 1999;58:215-222.
15. Amrutkar JR, Gattani SG. Chitosan chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS PharmSciTech. 2009;10:670-677.
16. Shah R, Patel S, Patel H, Pandey S, Shah S, Shah D. Formulation development of carvedilol compression coated tablet. Pharm Dev Technol. 2011;16:1-10.
17. Ahmadi F, Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Mahzouni P, et al. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats. Drug Deliv. 2011;18:122-130.
18. Lopes CM, Sousa Lobo JM, Costa P, Pinto JF. Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release. Drug Dev Ind Pharm. 2006;32:95-106.
19. Mura P, Maestrelli F, Cirri M. Development of enteric-coated pectin-based matrix tablets for colonic delivery of theophylline. J Drug Target. 2003;11:365-371.